Outlook Therapeutics Secures $31.8 Million in Unsecured Convertible Promissory Note: A Game-Changing Move in the World of Forex Trading
Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Notes Financing ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a leading biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of retinal diseases, announced today that it has entered into a Securities Purchase Agreement (SPA)…